Contact

All Stories

  1. Materialization of Information (MI) in Biology; 3-D Printing Inside the Cell: A productive analogy

    Article • Medical Hypotheses, October 2024, Elsevier

    Prof Dr Faruk Nuri Aykan

  2. Biophysical Approach to Understand Life and Cancer

    Article • Aging and Cancer, September 2024, Wiley

    Prof Dr Faruk Nuri Aykan

  3. A Post-International Gastrointestinal Cancers’ Conference (IGICC) Position Statements

    Article • Journal of Hepatocellular Carcinoma, May 2024, Taylor & Francis

    Prof Dr Faruk Nuri Aykan

  4. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey

    Article • Future Oncology, August 2022, Taylor & Francis

    Prof Dr Faruk Nuri Aykan

  5. The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer

    Article • Journal of Gastrointestinal Cancer, November 2020, Springer Science + Business Media

    İsmail Beypinar, Prof Dr Faruk Nuri Aykan

  6. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

    Article • BMC Cancer, March 2020, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  7. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

    Article • BMJ Open, March 2020, BMJ

    Prof Dr Faruk Nuri Aykan

  8. Objective response rate assessment in oncology: Current situation and future expectations

    Article • World Journal of Clinical Oncology, February 2020, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Prof Dr Faruk Nuri Aykan

  9. Body Mass Index and Colorectal Cancer

    Article • February 2019, IntechOpen

    Prof Dr Faruk Nuri Aykan

  10. Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study

    Article • Surgical Oncology, September 2018, Elsevier

    Prof Dr Faruk Nuri Aykan

  11. Neoadjuvant volumetric modulated arc therapy in rectal cancer and the correlation of pathological response with diffusion-weighted MRI and apoptotic markers

    Article • Tumori Journal, May 2018, SAGE Publications

    Prof Dr Faruk Nuri Aykan, Emre Balık

  12. Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.

    Article • Journal of Clinical Oncology, February 2018, American Society of Clinical Oncology (ASCO)

    Prof Dr Faruk Nuri Aykan

  13. Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients

    Article • Journal of Gastrointestinal Cancer, January 2018, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  14. Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report

    Article • World Journal of Radiology, September 2017, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Prof Dr Faruk Nuri Aykan

  15. Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer

    Article • Molecular and Clinical Oncology, September 2017, Spandidos Publications

    Prof Dr Faruk Nuri Aykan

  16. Efficacy of obesity in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy combinations: A Turkish Oncology Group Study

    Article • Annals of Oncology, October 2016, Elsevier

    Prof Dr Faruk Nuri Aykan

  17. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study

    Article • Journal of Gastrointestinal Cancer, April 2016, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  18. Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients

    Article • Journal of Gastrointestinal Cancer, April 2016, Springer Science + Business Media

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  19. Red meat and colorectal cancer

    Article • Oncology Reviews, December 2015, PAGEPress Publications

    Prof Dr Faruk Nuri Aykan

  20. Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma

    Article • Journal of Gastrointestinal Cancer, December 2015, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  21. Neoadjuvant Volumetric Modulated Arc Therapy Simultaneous Integrated Boost (SIB-VMAT) With Concurrent Chemotherapy in Rectal Adenocarcinomas and the Correlation of Pathological Response With Diffusion-Weighted MRI and Apoptotic Markers

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2015, Elsevier

    Prof Dr Faruk Nuri Aykan

  22. Clinical significance of serum claudin-1 and claudin-7 levels in patients with colorectal cancer

    Article • Molecular and Clinical Oncology, August 2015, Spandidos Publications

    Prof Dr Faruk Nuri Aykan

  23. Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma

    Article • Revista de Oncología, July 2015, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  24. Serum neural precursor cell-expressed, developmentally down regulated 9 (NEDD9) level may have a prognostic role in patients with gastric cancer

    Article • Biomedicine & Pharmacotherapy, July 2015, Elsevier

    Prof Dr Faruk Nuri Aykan

  25. Red meat subtypes and colorectal cancer risk

    Article • International Journal of Cancer, June 2015, Wiley

    Prof Dr Faruk Nuri Aykan

  26. P-256 An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)

    Article • Annals of Oncology, June 2015, Elsevier

    Prof Dr Faruk Nuri Aykan

  27. Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?

    Article • Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)

    Prof Dr Faruk Nuri Aykan

  28. Clinical significance of serum claudin-7 levels in patients with colorectal cancer.

    Article • Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)

    Prof Dr Faruk Nuri Aykan

  29. Prognostic roles of serum NEDD9 levels in patients with gastric cancer.

    Article • Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)

    Prof Dr Faruk Nuri Aykan

  30. Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial)

    Article • The Turkish Journal of Gastroenterology, March 2015, AVES Publishing Co.

    Prof Dr Faruk Nuri Aykan

  31. Clinical significance of serum vascular cell adhesion molecule-1(VCAM-1) in colorectal cancer.

    Article • Journal of Clinical Oncology, January 2015, American Society of Clinical Oncology (ASCO)

    Prof Dr Faruk Nuri Aykan

  32. Can Complementary 68Ga-DOTATATE and 18F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors?

    Article • Journal of Nuclear Medicine, October 2014, Society of Nuclear Medicine

    Prof Dr Faruk Nuri Aykan

  33. Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients

    Article • Tumor Biology, August 2014, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  34. The diagnostic, predictive, and prognostic role of serum cellular adhesion molecules (VCAM-1, EpCAM) levels in breast cancer patients.

    Article • Journal of Clinical Oncology, May 2014, American Society of Clinical Oncology (ASCO)

    Prof Dr Faruk Nuri Aykan

  35. Clinical significance of serum protein and mRNA level of insulin-like growth factor-1 (IGF-1) in patients with hepatocellular carcinoma.

    Article • Journal of Clinical Oncology, January 2014, American Society of Clinical Oncology (ASCO)

    Prof Dr Faruk Nuri Aykan

  36. Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma

    Article • Tumor Biology, November 2013, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  37. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy

    Article • Medical Oncology, August 2013, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  38. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?

    Article • Medical Oncology, July 2013, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  39. Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC)

    Article • Revista de Oncología, October 2012, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  40. Intercellular Communication

    Article • April 2012, IntechOpen

    Prof Dr Faruk Nuri Aykan

  41. Comparison of two different adjuvant treatment approaches for patients with locally advanced gastric cancer.

    Article • Journal of Clinical Oncology, May 2011, American Society of Clinical Oncology (ASCO)

    Prof Dr Faruk Nuri Aykan

  42. Profile of the colorectal (CRC) cancer (Ca) patients (PTS) in Turkey: A cross-sectional disease registry study—A Turkish Oncology Group trial.

    Article • Journal of Clinical Oncology, February 2011, American Society of Clinical Oncology (ASCO)

    Prof Dr Faruk Nuri Aykan

  43. Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer

    Article • Investigational New Drugs, September 2008, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  44. The role of UFT in advanced gastric cancer

    Article • Annals of Oncology, January 2008, Oxford University Press (OUP)

    Prof Dr Faruk Nuri Aykan

  45. Adjuvant chemoradiation for patients with adenocarcinoma of the pancreas: an expirence of single institute

    Article • Medical Oncology, June 2007, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  46. Message-adjusted network (MAN) hypothesis in gastro-entero-pancreatic (GEP) endocrine system

    Article • Medical Hypotheses, January 2007, Elsevier

    Prof Dr Faruk Nuri Aykan

  47. XELOX Followed by XELIRI or the Reverse Sequence in Advanced Colorectal Cancer

    Article • Oncology, January 2007, Karger Publishers

    Prof Dr Faruk Nuri Aykan

  48. upper gastrointestinal tumors

    Article • Annals of Oncology, September 2006, Elsevier

    Prof Dr Faruk Nuri Aykan

  49. Penile metastasis of cutaneous malignant melanoma: a true hematogenous spread?

    Article • Melanoma Research, June 2006, Wolters Kluwer Health

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  50. Prognostic Features and Survival of Inoperable Hepatocellular Carcinoma in Turkish Patients With Cirrhosis

    Article • American Journal of Clinical Oncology, October 2004, Wolters Kluwer Health

    Prof Dr Faruk Nuri Aykan

  51. Long-term survival after curative resection for pancreatic ductal adenocarcinoma

    Article • Journal of Clinical Oncology, July 2004, American Society of Clinical Oncology (ASCO)

    Prof Dr Faruk Nuri Aykan

  52. Timing of Death From Tumor Recurrence After Curative Gastrectomy for Gastric Cancer

    Article • American Journal of Clinical Oncology, April 2004, Wolters Kluwer Health

    Prof Dr Faruk Nuri Aykan

  53. A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer

    Article • Annals of Oncology, July 2003, Elsevier

    Prof Dr Faruk Nuri Aykan

  54. Colorectal Cancer in Young Patients: Characteristics and Outcome

    Article • The Tohoku Journal of Experimental Medicine, January 2003, Tohoku University Medical Press

    Prof Dr Faruk Nuri Aykan

  55. Adjuvant Intraperitoneal Chemotherapy With Cisplatinum, Mitoxantrone, 5-Fluorouracil, and Calcium Folinate in Patients With Gastric Cancer

    Article • American Journal of Clinical Oncology, December 2002, Wolters Kluwer Health

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  56. Prognostic Factors in Pancreatic Carcinoma

    Article • American Journal of Clinical Oncology, December 2001, Wolters Kluwer Health

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  57. Measurement of Serum CA 19-9 May Be More Valuable Than CEA in Prediction of Recurrence in Patients With Gastric Cancer

    Article • American Journal of Clinical Oncology, April 2001, Wolters Kluwer Health

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  58. Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer

    Article • British Journal of Cancer, January 2001, Springer Science + Business Media

    Prof Dr Faruk Nuri Aykan

  59. The Roles of Chemotherapy and Surgery in Gastric Carcinoma and the Influence of Prognostic Factors on Survival

    Article • American Journal of Clinical Oncology, February 2000, Wolters Kluwer Health

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  60. Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil and calcium folinate in stage II–III gastric cancer

    Article • European Journal of Cancer, September 1999, Elsevier

    Prof Dr Faruk Nuri Aykan

  61. Oral uracil/tegafur (UFT) plus leucovorin (LV) in patients with metastatic colorectal cancer (CRC)

    Article • European Journal of Cancer, September 1999, Elsevier

    Prof Dr Faruk Nuri Aykan

  62. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5‐fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma

    Article • Cancer, December 1998, Wiley

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  63. The efficacy of a five-drug antiemetic combination during chemotherapy regimens containing cisplatin or cyclophosphamide-doxorubicin

    Article • Journal of Pain and Symptom Management, April 1993, Elsevier

    Prof Dr Faruk Nuri Aykan